Gilead Sciences (XSWX:GILD) Beginning Cash Position: CHF6,097 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GILD Gilead Sciences Inc XSWX:GILD
68 GF Score
Price CHF118.78
GF Value CHF86.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Gilead Sciences Beginning Cash Position?

Gilead Sciences XSWX:GILD 68 Beginning Cash Position is CHF6,097 Mil as of Jun. 2026. GuruFocus rates XSWX:GILD with a GF Score™ of 68/100 and a GF Value™ of CHF86.75 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Gilead Sciences's Beginning Cash Position for the quarter that ended in Jun. 2026 was CHF6,097 Mil.

Gilead Sciences's quarterly Beginning Cash Position increased from Dec. 2025 (CHF5,841 Mil) to Mar. 2026 (CHF5,955 Mil) and increased from Mar. 2026 (CHF5,955 Mil) to Jun. 2026 (CHF6,097 Mil).

Gilead Sciences's annual Beginning Cash Position increased from Dec. 2023 (CHF4,680 Mil) to Dec. 2024 (CHF5,425 Mil) and increased from Dec. 2024 (CHF5,425 Mil) to Dec. 2025 (CHF7,962 Mil).

Gilead Sciences Beginning Cash Position Related Terms

Gilead Sciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Beginning Cash Position Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,523.24 4,972.88 4,680.30 5,425.39 7,961.83

Gilead Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,446.24 4,094.34 5,841.28 5,955.14 6,097.06
XSWX:GILD
68GF Score
Gilead Sciences Inc XSWX:GILD
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of CHF6,097 Mil mean?
Gilead Sciences (XSWX:GILD) has a Beginning Cash Position of CHF6,097 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Beginning Cash Position too high?
Gilead Sciences' current Beginning Cash Position is CHF6,097 Mil. Overall, Gilead Sciences has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Beginning Cash Position compare to PFE and BMY?
Gilead Sciences' Beginning Cash Position of CHF6,097 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Beginning Cash Position is CHF6,097 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (XSWX:GILD) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF86.75, compared to a current price of CHF118.78 — trading 36.9% above its estimated fair value. The current Beginning Cash Position is CHF6,097 Mil. Gilead Sciences' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Gilead Sciences (XSWX:GILD), the current Beginning Cash Position is CHF6,097 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (XSWX:GILD) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of CHF118.78 is trading 36.9% above its estimated GF Value™ of CHF86.75. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for XSWX:GILD:

  • Beginning Cash Position: CHF6,097 Mil
  • GF Value™: CHF86.75 vs. price of CHF118.78 (36.9% above fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the XSWX:GILD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
68GF Score

Get the complete analysis for XSWX:GILD

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF118.78
Price
CHF86.75
GF Value